EW vs TFX
EW: Edwards Lifesciences is a global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. TFX: Teleflex provides essential, specialty medical technologies used in critical care and surgical procedures to improve patient outcomes.
Side-by-side fundamentals
| Metric | EW | TFX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $84.24 | $124.19 | |
| Market cap | $48.6B | $5.3B | |
| P/E as of 2026-10-08 | 48.74 | n/a | |
| Net margin FY2025, SEC XBRL | +17.7% | -45.4% | EW higher |
| Gross margin FY2025, SEC XBRL | +78.0% | +56.2% | EW higher |
| Operating margin FY2025, SEC XBRL | +20.8% | +5.9% | EW higher |
| ROE FY2025, SEC XBRL | +10.4% | -29.0% | EW higher |
| ROA FY2025, SEC XBRL | +7.8% | -13.0% | EW higher |
| Debt / equity as of 2026-09-03 | 0.06 | 0.97 | EW lower |
| Revenue growth (YoY) as of 2026-09-03 | +14.6% | -14.5% | EW higher |
| Revenue CAGR (3y) SEC XBRL | +10.8% | -10.6% | EW higher |
| Dividend yield as of 2026-09-02 | n/a | +1.1% | |
| Dividend streak (yrs) SEC XBRL | 0 | 18 | TFX higher |
| Beta as of 2026-09-03 | 0.55 | 0.74 | |
| 1-year return as of 2026-10-08 close | +11.2% | -3.3% | EW higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.